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Abstract  
Cardiovascular and skeletal muscle manifestations constitute important comorbidities in 
COPD, with systemic inflammation proposed as a common mechanistic link.  Fibrinogen has 
prognostic role in COPD. We aimed to determine whether aortic stiffness and quadriceps 
weakness are linked in COPD, and whether they are associated with the systemic 
inflammatory mediator – fibrinogen. 
Aortic pulse wave velocity (aPWV), quadriceps maximal volitional contraction force (QMVC) 
and fibrinogen were measured in 729, stable, GOLD stage II-IV COPD patients.  
The cardiovascular and muscular manifestations exist independently (p=0.22, Chi squared). 
Fibrinogen was not associated with aPWV or QMVC (p=0.628 and p=0.621 respectively), 
making inflammation, as measured by plasma fibrinogen, an unlikely common aetiological 
factor. 
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Introduction  
Cardiovascular disease and locomotor muscle dysfunction are two important comorbidities 
in COPD, occurring in up to 50% 1 2 of patients, and relating to both increased healthcare 
utilization and mortality, thus representing potential therapeutic targets. Both share common 
risk factors, including smoking, exacerbations and physical inactivity, but systemic 
inflammation has been also proposed as a mechanistic link between them.  If so, novel anti-
inflammatory therapies might simultaneously target both manifestations.  Fibrinogen is the 
only inflammatory biomarker with regulatory approval as a drug development tool in COPD 
but hitherto, the value of fibrinogen in predicting these phenotypes has not been examined. 
 
In the “Evaluating the Role of Inflammation in Chronic Airways disease” (ERICA) study we 
investigated whether cardiovascular and skeletal muscle manifestations overlap in COPD and, 
whether these manifestations are associated with plasma fibrinogen.  ERICA is unique among 
multicentre studies in objectively quantifying these non-pulmonary manifestations of COPD.  
 
Methods  
 
Methods have been described previously 3.  ERICA is a prospective, observational study that 
recruited subjects from hospital and community settings, and was registered with the UK 
Clinical Research Network Study Portfolio  
(http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=11101). Cambridge South 
Research Ethics Committee (reference 11/EE/0357) approved the study, and participants 
provided written consent to participate. 
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Subjects were aged 40-90 years with GOLD stage II-IV COPD judged by post-bronchodilator 
spirometry. Relevant exclusion criteria were alpha-1-antitrypsin deficiency or significant co-
existing pulmonary disease; subjects were clinically stable for >4 weeks. Comorbid disease 
was not an exclusion criterion.  
 
Subjects underwent multiple phenotypic assessments, including aortic pulse wave velocity 
(aPWV), quadriceps maximal volitional contraction force (QMVC), 6-minute walk distance 
(6MWD) and fibrinogen.  
 
APWV of >10m/s was chosen as a surrogate measure of cardiovascular disease 4. Quadriceps 
weakness was defined according to the gender-specific Seymour equation 2. Group 
‘Cardiovascular’ contained subjects with elevated aPWV alone, ‘Muscle’ contained subjects 
with skeletal muscle weakness only, ‘Both’ contained subjects with both manifestations and 
‘Neither’ had subjects with neither manifestation. 
 
Multiple linear regression analyses were conducted to estimate the dependence of QMVC 
and aPWV on fibrinogen, with adjustment for known or expected confounders. Non-normally 
distributed variables were log transformed prior to analysis. 
 
Chi-square testing was carried out to test whether QMVC and aPWV were independently 
associated.  
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Analyses were performed using R version 3.0.0 for Microsoft Windows with RStudio version 
0.98.953. 
 
Results 
746 people were screened; 729 met inclusion criteria and 617 subjects had both aPWV and 
QMVC measurements.  Table 1 describes baseline demographics for the whole cohort and 
phenotypic groups. The population had a mean age of 67 years, 61% were males, with mean 
FEV1 52.2 % predicted, mean aPWV of 10.3 m/s and mean QMVC of 30.6 kg (68.2% predicted). 
 
Of 617 subjects, 194 (31.4%) were classified as ‘Neither’, 137 (22.2%) as “Muscle”, 154 
(30.0%) as “Cardiovascular” and 132 (21.4%) as “Both” (Figure 1). Overall, 269 out of 617 
(43.6%) subjects had muscle weakness and 286 out of 617 (46.4%) had elevated aPWV. Chi-
square test confirmed that cardiovascular and skeletal muscle manifestations were 
independent (test statistic 1.49; p=0.22). 
 
Age, gender, supine heart rate, supine mean arterial pressure and diabetes were significantly 
associated with aPWV (eTable 2). Smoking history, FEV1, previous self-reported myocardial 
infarction, anti-hypertensive therapy and cholesterol lowering therapy were not significantly 
associated. 
 
QMVC was significantly and independently associated with age, gender, fat-free mass and 
FEV1 (eTable 3). Smoking history and height were not significant associations. 
 
Discussion 
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Cardiovascular and skeletal muscle manifestations are more prevalent in COPD than 
previously reported, but do not coexist more frequently than is expected by chance and 
therefore likely require different therapeutic approaches. Furthermore, fibrinogen was not 
associated with quadriceps strength or aortic stiffness, suggesting that it is unlikely to be 
useful in clinical trials addressing cardiovascular or skeletal muscle manifestations in COPD. 
Our findings do not support the concept that anti-inflammatory therapy aiming to reduce 
fibrinogen is likely to reduce aortic stiffness or improve quadriceps strength in COPD.   
 
Our estimate of cardiovascular comorbidity agrees with previous estimates. Associations with 
aPWV in our patients were similar to those previously observed in healthy subjects 4, 
Interestingly fibrinogen was not associated with arterial stiffness, despite prior reports of 
association of aPWV with Interleukin-6 and CRP; moreover we failed to find associations 
between WCC, CRP and aPWV or QMVC (eTables 4 - 13).  Furthermore, we did not find an 
association between FEV1 and aPWV, in contrast to  smaller studies5, suggesting that aPWV is 
not linked to the severity of airflow limitation in people diagnosed with COPD.   
 
In our cohort, the prevalence of quadriceps weakness (43.6%), is higher than previously 
reported 2. In COPD, muscle weakness precedes the development of whole body cachexia, 
with relative upper limb sparing 6, therefore measures other than QMVC (for example 
handgrip strength or bioimpedence) are likely to underestimate the prevalence of muscle 
dysfunction. 
 
This study is one of the few to have examined the co-existence of cardiac and muscle 
manifestations. Using different methodologies prior studies found lower prevalences; 
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Vanfleteren 7 reported 10% of patients in their cardiovascular cluster had muscle wasting 
while 7% of cachectic patients had a history of myocardial infarction.  Siebeling et al 8 estimate 
co-existence of cardiovascular and muscular comorbidities at 2-3%. 21.4% of our cohort 
exhibited both elevated aPWV and quadriceps weakness; chi-squared testing confirmed that 
there is not an independent, overlap syndrome. 
 
Our study supports recent data that refutes the link between low grade systemic 
inflammation and cardiovascular or muscle manifestations in COPD 7 9.  Persistent systemic 
inflammation is present in 16% of patients with COPD 10; given that we report prevalence of 
both APWV and QMVC is much higher than 16%, inflammation seems an improbable key 
aetiological factor. The cross-sectional nature of our data means that a temporal link between 
PWV and QMVC, or systemic inflammation cannot be assessed at this stage, although follow 
up of the cohort is ongoing. Additionally, it is important to note that our study allowed the 
cross-sectional assessments to be carried out over either a single visit or two visits within a 
three month period, therefore we acknowledge that in some patients inflammatory markers 
were measured on a separate day to aPWV and QMVC. A further limitation is that 112 
patients of the entire data set did not have the 3 key measures assessed here.  These patients 
were similar in most respects to the cohort analysed here but had a lower FEV1 and 6MWD 
(data not shown).  
 
In conclusion, cardiovascular and skeletal muscle manifestations are prevalent in COPD, with 
muscle weakness being commoner than previously thought. These extra-pulmonary 
manifestations are distinct, and need to be addressed individually. Neither aortic stiffness nor 
quadriceps weakness relate to plasma fibrinogen, suggesting that this is not a useful 
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biomarker for trials addressing these manifestations and that inflammation is an unlikely 
aetiological factor. 
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Table 1 Baseline demographics 
Variable Overall 
(n =729) 
 Neither  
 (n=194) 
Muscle  
(n=137) 
Cardiovascul
ar  
(n=154) 
Both  
(n=132) 
 
Age (years) 67 (8)  66 (7) *** 63 (8) *** 70 (7) *** 70 (7) *** 
Gender (%male) 60.6  58.3  54.7 67.5 62.9 
Smoking history 
(total pack years) 
47 (28)  45 (27) 47 (26) 51 (31) 47 (28) 
BMI (kg / m2) 27.3 (5.8)  26.3 (4.9) ** 26.9 (5.6) 27.1 (4.9) 28.3 (6.5) * 
Fat free mass (kg) 51.0 (11.1)  49.7 (10.6) 50.1 (11.2) 51.9 (10.5) 52.2 (11.9) 
CAT score (0-40) 20 (0,40)  17 (0,38) *** 22 (1,39)** 19 (3,40) 21.5 
(6,40)* 
SGRQ total score 51.4 (22.3)  44.2 
(21.2)*** 
57.4 
(21.5)*** 
47.7 (22.5)* 55.8 
(20.5)* 
FEV1 (L) 1.34 (0.53)  1.50 
(0.52)*** 
1.31 (0.53)  1.32 (0.50) 1.26 (0.50) 
FEV1 (% predicted) 52.2 (16.1)  57.4 
(14.2)*** 
49.4 (16.3)* 51.8 (16.4) 50.5 (15.8) 
FEV1/FVC 0.48 (0.13)  0.49 (0.12) 0.48 (0.13) 0.47 (0.12) 0.49 (0.13) 
Muscle Indices 
QMVC (kg) 30.6 (11.5)  36.1 (10.1) 23.4 (7.9) 36.7 (10.7) 22.7 (8.2) 
QMVC (% 
predicted) 
68.2 (20.7)  81.4 (15.3) 51.5 (12.0) 82.2 (14.9) 50.2 (12.9) 
SPPB  total score 10 (1,12)  11 (3,12) *** 10 (3,12) 11 (4,12) ** 9 (2,12) *** 
6 MW distance (m) 345 (130)  404 (104)*** 338 (129) 361 (125) 282 
(132)*** 
Cardiovascular Indices 
Supine MAP (mm 
Hg) 
98 (12)  96 (11)* 95 (10)*** 100 (10)* 100 (11)* 
APWV (m/s) 10.3 (2.6)  8.3 (1.1) 8.3 (1.1) 12.2 (2.0) 12.7 (1.9) 
Inflammatory markers 
Fibrinogen (g/dL)  3.49 (0.86)  3.44 (0.95) 3.41 (0.76) 3.49 (0.78) 3.52 (0.90) 
hsCRP (mg/L) 6.57 (12.1)  7.45 (19.7) 6.11 (8.13) 5.63 (6.95) 6.365 
(6.55) 
WCC (x109/L) 7.50 (2.16)  7.32 (2.15) 7.19 (2.18) 7.42 (1.95) 7.70 (2.38) 
Comorbidities 
Exacerbations per 
year 
1.9 (2.1)  1.71 (1.8) 2.2 (2.0)* 1.81 (2.34) 2.2 (2.3)* 
Diabetes (%) 11.4  6.3 7.2 10.4 18.3** 
Anti-hypertensive 
therapy (%) 
35.9  31.4 28.9 39.0 43.9 * 
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Cholesterol 
lowering therapy 
(%) 
32.6  22.8 28.5 37.9 ** 43.8 *** 
Previous 
myocardial 
infarction (%) 
7.9  6.3 6.6 9.1 9.2 
 
Table 1: Baseline demographics for overall cohort (n = 729) and phenotypic groups. Values 
expressed as mean (standard deviation) for continuous variables and median (range) for 
discrete variables. Group ‘Neither’ (n=194) represents subjects with neither elevated aortic 
pulse wave velocity nor skeletal muscle weakness. Group ‘Muscle’ (n=137) represents 
subjects with skeletal muscle weakness alone. Group ‘Cardiovascular’ (n=154) represents 
subjects with cardiovascular manifestation, defined as elevated aortic pulse wave velocity, 
alone, and group ‘Both’ (n=132) contains subjects demonstrating both skeletal muscle 
weakness and elevated aortic pulse wave velocity. Skeletal muscle weakness according to 
predicted quadriceps maximal volitional contraction, based on equations developed by 
Seymour et al 2 and elevated aortic pulse wave velocity defined as >10 m/s. 
 
* p-value <0.05, ** p-value <0.01 and *** p-value of <0.001 for significant differences across 
groups. For continuous variables, the p-value represents differences between overall mean 
and group mean. For ordinal and binary variables, p-value represents differences between 
group ‘Neither’ and the remaining groups. Adjustments have not been made for multiple 
comparisons. 
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List of abbreviations: BMI = body mass index, FEV1 = forced expiratory volume in 1 second, 
QMVC = quadriceps maximal volitional contraction, SPPB = short physical performance 
battery, 6MW = 6 minute walk, MAP = mean arterial pressure, aPWV = aortic pulse wave 
velocity, CRP = C-reactive protein, WCC = white cell count, CAT = COPD assessment test, 
SGRQ = St George’s respiratory questionnaire 
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Figure 1 Relationship between fibrinogen and APWV and QMVC 
 
Figure 1: Scatterplot demonstrating relationship between: (a) fibrinogen (g/L) and arterial 
stiffness, as measured by aortic pulse wave velocity (PWV) (m/s) in 651 subjects with COPD, 
with Spearman correlation of 0.05, p = 0.25; and (b) fibrinogen (g/L) and quadriceps 
weakness, as measured by quadriceps volitional contraction (QMVC) (kg) in 684 subjects 
with COPD, with Spearman correlation -0.10 and p=0.009. 
 
